Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate 0.2% Nanoemulsion Eye Drops in Patients With Dry Eye Disease (DED)
Conditions
Interventions
Brimonidine Tartrate
Placebos
Locations
16
United States
Aesthetic Eye Care Institute/David Wirta, MD and Associates
Newport Beach, California, United States
Martel Medical Eye Group
Rancho Cordova, California, United States
Rand Eye Institute
Pompano Beach, Florida, United States
Chicago Cornea Consultants
Hoffman Estates, Illinois, United States
Heart of America Eye Care, P. A.
Mission, Kansas, United States
Ophthalmology Associates
St Louis, Missouri, United States
Start Date
December 3, 2018
Primary Completion Date
February 25, 2019
Completion Date
February 25, 2019
Last Updated
July 18, 2022
NCT07463950
NCT07363824
NCT07396441
NCT07298811
NCT07295691
NCT07191847
Lead Sponsor
Ocugen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions